Exchange

Nasdaq

Every company in the roster listed on Nasdaq.

Views

280 of 280 companies

Company	Pipeline	Most advanced	Next readout
Editas Medicine, Inc.EDIT · Nasdaq	1 asset: 1 Ph 2	EDIT-301Phase 1/2 · Severe Sickle Cell Disease	None on record
Eikon TherapeuticsEIKN · Nasdaq	1 asset: 1 Ph 3	EIK1001Phase 2/3 · Non-Small Cell Lung Cancer	Dec 2026EIK1001 · Phase 2
Enliven TherapeuticsELVN · Nasdaq	1 asset: 1 Ph 1	ELVN-001Phase 1 · Chronic Myeloid Leukemia	Dec 2027ELVN-001 · Phase 1
Enlivex TherapeuticsENLV · Nasdaq	1 asset: 1 Ph 2	AllocetraPhase 2 · Osteoarthritis	Feb 2027Allocetra · Phase 2
Fulcrum TherapeuticsFULC · Nasdaq	1 asset: 1 Ph 2	LosmapimodPhase 2 · Facioscapulohumeral Muscular Dystrophy	None on record
GRI Bio, Inc.GRI · Nasdaq	1 asset: 1 other	GRI-0803Systemic Lupus Erythematosus	None on record
Galmed Pharmaceuticals Ltd.EOCN · Nasdaq	1 asset: 1 Ph 3	AramcholPhase 3 · Metabolic Dysfunction-Associated Steatohepatitis	None on record
Genelux CorporationGNLX · Nasdaq	1 asset: 1 Ph 3	Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer	Dec 2026Olvimulogene nanivacirepvec · Phase 3
Genenta Science S.p.A.GNTA · Nasdaq	1 asset: 1 Ph 2	TemferonPhase 1/2 · Glioblastoma	None on record
Genprex, Inc.GNPX · Nasdaq	1 asset: 1 Ph 2	Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung Cancer	Dec 2027Quaratusugene Ozeplasmid · Phase 1/2
Geron CorporationGERN · Nasdaq	1 asset: 1 approved	Approved assets only	Feb 2027Imetelstat · Phase 1
Gossamer BioGOSS · Nasdaq	1 asset: 1 Ph 3	SeralutinibPhase 3 · Pulmonary Arterial Hypertension	Dec 2026Seralutinib · Phase 3
Grace TherapeuticsGRCE · Nasdaq	1 asset: 1 Ph 3	NimodipinePhase 3 · Subarachnoid Hemorrhage	None on record
Gyre TherapeuticsGYRE · Nasdaq	1 asset: 1 Ph 1	F230Phase 1 · Hypertension	None on record
HumacyteHUMA · Nasdaq	1 asset: 1 approved	Approved assets only	None on record
INmune BioINMB · Nasdaq	1 asset: 1 Ph 2	XPro1595Phase 2 · Alzheimer's DiseasePartial signal	None on record
ITM Oncologics GmbHITM · Nasdaq	1 asset: 1 Ph 2	177Lu-DPI-4452Phase 1/2 · Non-Small Cell Lung Cancer	None on record
Immuneering CorporationIMRX · Nasdaq	1 asset: 1 Ph 2	IMM-1-104Phase 1/2 · Non-Small Cell Lung Cancer	None on record
Inmagene BiopharmaceuticalsIMA · Nasdaq	1 asset: 1 Ph 2	IMG-007Phase 2 · Atopic DermatitisWeak signal	Dec 2027IMG-007 · Phase 2
Inovio Pharmaceuticals, Inc.INO · Nasdaq	1 asset: 1 Ph 2	INO-3107Phase 1/2 · Recurrent Respiratory Papillomatosis	None on record
InventivaIVA · Nasdaq	1 asset: 1 Ph 3	LanifibranorPhase 3 · Type 2 DiabetesPartial signal	30 Sep 2027Lanifibranor · Phase 3
Jaguar HealthJAGX · Nasdaq	1 asset: 1 approved	Approved assets only	Dec 2026Crofelemer · Phase 2/3
Jasper Therapeutics, Inc.JSPR · Nasdaq	1 asset: 1 Ph 2	BriquilimabPhase 2 · AsthmaPartial signal	None on record
Kiora Pharmaceuticals, Inc.KPRX · Nasdaq	1 asset: 1 Ph 2	KIO-301Phase 2 · Retinitis Pigmentosa	Aug 2027KIO-301 · Phase 2
LB PharmaceuticalsLBRX · Nasdaq	1 asset: 1 Ph 3	LB-102 (methylated amisulpride)Phase 3 · SchizophreniaReliable signal	None on record
Lexeo TherapeuticsLXEO · Nasdaq	1 asset: 1 Ph 2	LX1001Phase 1/2 · Alzheimer's DiseaseWeak signal	Nov 2028LX1001 · Phase 1
Lipocine Inc.LPCN · Nasdaq	1 asset: 1 approved	Approved assets only	None on record
Lisata TherapeuticsLSTA · Nasdaq	1 asset: 1 Ph 2	certepetidePhase 2 · Pancreatic Cancer	None on record
Longeveron (NASDAQ: LGVN)LGVN · Nasdaq	1 asset: 1 Ph 2	LaromestrocelPhase 2 · Alzheimer's DiseasePartial signal	None on record
MapLight TherapeuticsMPLT · Nasdaq	1 asset: 1 Ph 2	ML-007C-MAPhase 2 · SchizophreniaPartial signal	Dec 2027ML-007C-MA · Phase 2
Matinas BioPharmaMTNB · Nasdaq	1 asset: 1 Ph 3	MAT2203Phase 3 · Cryptococcal Meningitis	None on record
Maze TherapeuticsMAZE · Nasdaq	1 asset: 1 Ph 2	MZE829Phase 2 · Chronic Kidney Disease	None on record
MiNK Therapeutics, Inc.INKT · Nasdaq	1 asset: 1 Ph 2	agenT-797Phase 2 · Gastric CancerWeak signal	Jun 2027agenT-797 · Phase 2
Mineralys TherapeuticsMLYS · Nasdaq	1 asset: 1 Ph 3	LorundrostatPhase 3 · HypertensionReliable signal	None on record
Minerva NeurosciencesNERV · Nasdaq	1 asset: 1 Ph 3	RoluperidonePhase 3 · SchizophreniaPartial signal	Dec 2027Roluperidone · Phase 3
MoleculinMBRX · Nasdaq	1 asset: 1 Ph 3	AnnamycinPhase 2/3 · Acute Myeloid Leukemia	Aug 2029Annamycin · Phase 2/3
MoonLake ImmunotherapeuticsMLTX · Nasdaq	1 asset: 1 Ph 3	sonelokimabPhase 3 · Psoriatic ArthritisReliable signal	15 Jan 2027sonelokimab · Phase 3
NRx PharmaceuticalsNRXP · Nasdaq	1 asset: 1 Ph 3	NRX-101Phase 3 · Bipolar Depression	None on record
NanobiotixNBTX · Nasdaq	1 asset: 1 Ph 3	NBTXR3Phase 3 · Non-Small Cell Lung Cancer	30 Apr 2027NBTXR3 · Phase 1
NewAmsterdam PharmaNAMS · Nasdaq	1 asset: 1 Ph 3	ObicetrapibPhase 3 · Type 2 DiabetesPartial signal	Nov 2026Obicetrapib · Phase 3
Nuvectis PharmaNVCT · Nasdaq	1 asset: 1 Ph 1	NXP900Phase 1 · Non-Small Cell Lung Cancer	Dec 2026NXP900 · Phase 1
Obsidian Therapeutics, Inc.OBX · Nasdaq	1 asset: 1 Ph 2	OBX-115Phase 1/2 · Non-Small Cell Lung Cancer	30 Jun 2029OBX-115 · Phase 1/2
Oncolytics Biotech Inc.ONCY · Nasdaq	1 asset: 1 Ph 3	PelareorepPhase 3 · Advanced Metastatic Colorectal Cancer	30 Jul 2027Pelareorep · Phase 1/2
Opus Genetics, Inc.IRD · Nasdaq	1 asset: 1 other	OPGx-LCA5Leber Congenital Amaurosis	None on record
OramedORMP · Nasdaq	1 asset: 1 Ph 3	ORMD-0801Phase 3 · Type 2 DiabetesPartial signal	25 Apr 2027ORMD-0801 · Phase 3
PRECISION BIOSCIENCES INCDTIL · Nasdaq	1 asset: 1 Ph 1	Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis	1 Dec 2026Azercabtagene zapreleucel · Phase 1
Palisade BioPALI · Nasdaq	1 asset: 1 Ph 2	PALI-2108Phase 2 · Ulcerative ColitisPartial signal	Oct 2027PALI-2108 · Phase 2
Pluri Inc.PLUR · Nasdaq	1 asset: 1 Ph 3	PLX-PADPhase 3 · Critical Limb Ischemia	None on record
ProKidneyPROK · Nasdaq	1 asset: 1 Ph 3	RilparencelPhase 3 · Chronic Kidney DiseaseWeak signal	Dec 2029Rilparencel · Phase 3
ProMIS Neurosciences, Inc.PMN · Nasdaq	1 asset: 1 Ph 1	PMN310Phase 1 · Alzheimer's Disease	Dec 2026PMN310 · Phase 1
Protara TherapeuticsTARA · Nasdaq	1 asset: 1 Ph 3	TARA-002Phase 3 · Non-Muscle Invasive Bladder Cancer	Dec 2026TARA-002 · Phase 2
PulmatrixPULM · Nasdaq	1 asset: 1 Ph 2	PUR1900Phase 2 · Allergic Bronchopulmonary Aspergillosis	None on record
Pyxis OncologyPYXS · Nasdaq	1 asset: 1 Ph 2	PYX-201Phase 1/2 · Solid Tumors	6 Dec 2027PYX-201 · Phase 1/2
Q32 BioQTTB · Nasdaq	1 asset: 1 Ph 2	BempikibartPhase 2 · Atopic Dermatitis	None on record
Quince TherapeuticsQNCX · Nasdaq	1 asset: 1 Ph 2	LAM-001Phase 2 · Bronchiolitis Obliterans Syndrome	Mar 2028LAM-001 · Phase 2
Rapport Therapeutics, Inc.RAPP · Nasdaq	1 asset: 1 Ph 3	RAP-219Phase 3 · EpilepsyWeak signal	3 Feb 2028RAP-219 · Phase 2
RedHill BiopharmaRDHL · Nasdaq	1 asset: 1 approved	Approved assets only	None on record
Rockwell MedicalRMTI · Nasdaq	1 asset: 1 approved	Approved assets only	None on record
Sagimet Biosciences Inc.SGMT · Nasdaq	1 asset: 1 Ph 3	DenifanstatPhase 3 · MASH / NASHReliable signal	None on record
Savara Inc.SVRA · Nasdaq	1 asset: 1 Ph 3	molgramostimPhase 3 · Autoimmune Pulmonary Alveolar Proteinosis	Jun 2027molgramostim · Phase 3
Scholar RockSRRK · Nasdaq	1 asset: 1 Ph 3	apitegromabPhase 3 · Spinal Muscular AtrophyPartial signal	1 Nov 2026apitegromab · Phase 3
Seaport TherapeuticsSPTX · Nasdaq	1 asset: 1 Ph 2	GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder	Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2
Shattuck Labs, Inc.STTK · Nasdaq	1 asset: 1 Ph 1	SL-172154Phase 1 · Higher-Risk Myelodysplastic Syndromes	None on record
Silence TherapeuticsSLN · Nasdaq	1 asset: 1 Ph 2	ZerlasiranPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal	None on record
Skye BioscienceSKYE · Nasdaq	1 asset: 1 Ph 2	nimacimabPhase 2 · Obesity	20 Nov 2026nimacimab · Phase 2
SoligenixSNGX · Nasdaq	1 asset: 1 Ph 3	Synthetic hypericinPhase 3 · Cutaneous T-Cell Lymphoma	None on record
Structure TherapeuticsGPCR · Nasdaq	1 asset: 1 Ph 3	aleniglipronPhase 3 · ObesityPartial signal	Sep 2028aleniglipron · Phase 3
Summit TherapeuticsSMMT · Nasdaq	1 asset: 1 Ph 3	IvonescimabPhase 3 · Non-Small Cell Lung CancerWeak signal	Dec 2026Ivonescimab · Phase 3
Tectonic TherapeuticTECX · Nasdaq	1 asset: 1 Ph 2	Fc-relaxin fusion protein (TX45)Phase 2 · Hypertension	24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2
Tempest TherapeuticsTPST · Nasdaq	1 asset: 1 Ph 3	TPST-1120Phase 3 · Hepatocellular Carcinoma	Dec 2028TPST-1120 · Phase 3
Tenax TherapeuticsTENX · Nasdaq	1 asset: 1 Ph 3	LevosimendanPhase 3 · Heart FailurePartial signal	30 Jun 2028Levosimendan · Phase 3
Tiziana Life Sciences Ltd.TLSA · Nasdaq	1 asset: 1 Ph 2	ForalumabPhase 2 · Multiple Sclerosis	1 Apr 2027Foralumab · Phase 2
Trevi Therapeutics, Inc.TRVI · Nasdaq	1 asset: 1 Ph 3	Nalbuphine ERPhase 3 · Prurigo Nodularis	Sep 2027Nalbuphine ER · Phase 2
TuHURA BiosciencesHURA · Nasdaq	1 asset: 1 other	IFx-2.0Merkel Cell Carcinoma	None on record
Unicycive TherapeuticsUNCY · Nasdaq	1 asset: 1 Ph 2	Oxylanthanum carbonatePhase 2 · Chronic Kidney DiseaseWeak signal	None on record
Upstream BioUPB · Nasdaq	1 asset: 1 Ph 2	verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal	Sep 2027verekitug · Phase 2
Vericel CorporationVCEL · Nasdaq	1 asset: 1 approved	Approved assets only	Feb 2030autologous cultured chondrocytes on porcine collagen membrane · Phase 3
Vir BiotechnologyVIR · Nasdaq	1 asset: 1 Ph 2	Tobevibart (VIR-3434)Phase 2 · Chronic Hepatitis Delta	None on record
Xenon PharmaceuticalsXENE · Nasdaq	1 asset: 1 Ph 3	AzetukalnerPhase 3 · Major Depressive DisorderReliable signal	Jan 2027Azetukalner · Phase 3
Xilio Development, Inc.XLO · Nasdaq	1 asset: 1 Ph 2	XTX501Phase 1/2 · Non-Small Cell Lung Cancer	Nov 2029XTX501 · Phase 1/2